Applied DNA Sciences, Inc. a company involved with PCR-based DNA technologies, acquired Spindle Biotech Inc., an early-stage, private biotech company developing next-generation RNA manufacturing technologies.
The acquisition leverages the company’s LinearDNA platform that enables efficient chemical modification of DNA templates and the high binding affinity of Spindle’s high-performance RNA polymerase (RNAP) for chemically modified DNA templates. The goal is to deliver multiple advantages over conventional plasmid DNA-based mRNA production, including: the prevention or reduction of double-stranded RNA (dsRNA) contamination resulting in higher target mRNA yields; delivery of IVT templates in as little as 14 days for milligram scale and 30 days for gram scale; and reduced mRNA manufacturing complexities.
